Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C round brings $52mm to Deciphera

Executive Summary

Deciphera Pharmaceuticals LLC (small-molecule cancer therapies) raised $52mm in its Series C round to lead investors Redmile Group, Viking Global Investors, and Sphera Global Healthcare Fund, which were joined by existing investors including New Leaf Venture Partners. Funds will support ongoing development of DCC2618 (in Phase I for gastrointestinal stromal tumors, aggressive systemic mastocytosis, and malignant gliomas) and DCC3014 (Phase I for advanced malignancies). Deciphera last raised funds through a Series B round that began at $75mm in 2015 and closed at over $90mm last year.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies